Cortisol 11-Beta-Ketoreductase Deficiency

Cortisone reductase deficiency (CRD) is a rare genetic condition where the body cannot properly reactivate cortisone into cortisol inside cells. Normally, an enzyme called 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) “recycles” inactive cortisone back to active cortisol (this local inside-cell recycling is called pre-receptor metabolism). In CRD, that recycling is weak, so the body “thinks” cortisol is low, the brain raises ACTH, and the adrenals make too many androgens, causing acne, hirsutism, irregular periods or early puberty—despite blood cortisol often looking near-normal. CRD is usually due to variants in HSD11B1 (the 11β-HSD1 enzyme) or H6PD (a partner enzyme that supplies the NADPH cofactor). Oxford Academic+3PubMed+3Bioscientifica+3

Cortisone reductase deficiency (CRD)—a disorder caused by impaired 11-beta-ketoreduction of cortisone to cortisol by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). In practice, “cortisol 11-beta-ketoreductase deficiency” describes the same biology: the body cannot efficiently regenerate cortisol from cortisone, so the brain thinks cortisol is “low,” drives up ACTH, and the adrenals make too many androgens as a by-product. That creates a PCOS-like picture (hirsutism, acne, irregular periods) in many females and premature pubarche in children, while blood cortisol in standard tests can look deceptively “okay.” PubMed Central+2Oxford Academic+2

Your body cycles cortisol (the active hormone) and cortisone (its inactive form). The “recycling” step—turning cortisone back into cortisol inside cells—depends on the enzyme 11β-HSD1 and a local power source called NADPH in the endoplasmic reticulum (ER). In cortisol 11-beta-ketoreductase deficiency, that recycling step is weak because 11β-HSD1 itself is faulty or because the ER cannot supply enough NADPH (usually from an enzyme called hexose-6-phosphate dehydrogenase, H6PD). As a result, tissues cannot regenerate enough cortisol locally. The pituitary senses “not enough cortisol effect” and pushes ACTH higher. ACTH stimulates the adrenal glands, which then overproduce androgens (like DHEA-S, androstenedione, testosterone). The outcome is hyperandrogenism (excess androgen effects) with normal or near-normal blood cortisol, and a characteristic urine steroid pattern showing the body favors cortisone over cortisol. Oxford Academic+3PubMed Central+3PubMed Central+3

Other names

• Cortisone reductase deficiency (CRD) – most widely used name in journals and registries. National Organization for Rare Disorders

• Apparent cortisone reductase deficiency (ACRD) – used when the functional defect looks like 11β-HSD1 failure even if the gene itself is normal (often due to H6PD problems). Oxford Academic

• 11β-HSD1 deficiency – emphasizes the enzyme that normally reduces cortisone to cortisol. PubMed Central

• H6PD-related cortisone reductase deficiency – highlights the NADPH-supply defect in the ER. Oxford Academic

• Cortisol 11-beta-ketoreductase deficiency – descriptive label for the same pathophysiology (reduced 11-keto → 11-hydroxy conversion). (Derived from the above primary sources.)

Types

Type 1 (primary 11β-HSD1 deficiency).
Caused by pathogenic variants in HSD11B1 that reduce or abolish 11β-HSD1’s oxo-reductase activity. These patients can show a milder spectrum, sometimes presenting later; several missense variants (e.g., R137C, K187N) have been described. PubMed Central+1

Type 2 (cofactor/NADPH-supply defect).
Caused by inactivating mutations in H6PD. H6PD sits with 11β-HSD1 in the ER lumen and generates NADPH, the essential cofactor that lets 11β-HSD1 run as a reductase (cortisone → cortisol). Without H6PD, 11β-HSD1 cannot perform oxo-reduction, so cortisol regeneration fails—this is the most commonly reported mechanism in early case series. Oxford Academic+2PubMed Central+2

Note: This disorder is distinct from apparent mineralocorticoid excess (AME) due to 11β-HSD2 deficiency, which causes salt retention and hypertension; in CRD the main clinical theme is hyperandrogenism, not mineralocorticoid excess. Wikipedia

Causes

1. Pathogenic variants in H6PD (nonsense, missense, frameshift). These block ER NADPH generation, so 11β-HSD1 cannot reduce cortisone to cortisol. Oxford Academic+1

2. Pathogenic variants in HSD11B1 (11β-HSD1 enzyme). These directly impair the enzyme that does cortisone → cortisol. Examples include R137C and K187N. PubMed Central

3. Compound heterozygosity in either gene. Different faulty variants on each allele can combine to cause disease. (General genetic principle supported across cases.) PubMed Central

4. Promoter or regulatory variants in HSD11B1 lowering enzyme expression in tissues. (Mechanistic inference from genetic reports where coding variants were absent but function was impaired.) Oxford Academic

5. Gene variants that destabilize the ER redox environment (affecting NADPH/NADP⁺ balance) and indirectly hamper 11β-HSD1’s reductase function. PubMed

6. ER cofactor delivery problems (transport of glucose-6-phosphate into ER for H6PD), reducing local NADPH supply. (Physiologic mechanism of H6PD pathway.) PubMed

7. Loss-of-function alleles clustered in H6PD’s catalytic sites, preventing the first two steps of the ER pentose phosphate pathway and thus NADPH production. PubMed

8. Splice-site mutations in H6PD or HSD11B1 creating nonfunctional protein. (Reported mutational mechanisms across monogenic endocrine disorders; consistent with CRD series.) Oxford Academic

9. Large deletions/insertions encompassing part of H6PD or HSD11B1. Structural variants can abolish function. (Generalizable genetics with CRD case genetics emphasizing inactivating changes.) Oxford Academic

10. Epigenetic down-regulation of HSD11B1 expression (less common; hypothesized in “apparent” CRD where coding sequence is normal). Oxford Academic

11. Functional inhibition of 11β-HSD1 by drugs like carbenoxolone, a non-selective 11β-HSD inhibitor. This can create an acquired, reversible CRD-like state. PubMed Central+1

12. Experimental/clinical 11β-HSD1 inhibitors (developed for metabolic disease) can reduce cortisone → cortisol regeneration in target tissues. PNAS

13. Severe ER stress or redox imbalance limiting NADPH availability for 11β-HSD1 in specific tissues. (Mechanistic inference from H6PD biology.) PubMed

14. Rare post-translational defects affecting 11β-HSD1 folding/ER localization. (Mechanistic inference from enzyme in ER lumen.) PubMed Central

15. Pathway modifiers that raise androgen synthesis in the adrenal (e.g., increased flux through 17,20-lyase) can amplify the clinical impact of the recycling defect. (Endocrine inference consistent with hyperandrogenism patterns.) PubMed Central

16. Consanguinity increasing the chance of biallelic pathogenic variants in H6PD or HSD11B1. (General genetic risk factor in autosomal-recessive traits; CRD cases often familial.) PubMed Central

17. Tissue-specific low 11β-HSD1 expression from noncoding variants may lead to milder or late-onset forms focused in adipose or liver. (Supported by reports of “milder” CRD with HSD11B1 changes.) PubMed Central

18. Partial loss of function (hypomorphic alleles) producing borderline biochemical profiles that are unmasked during puberty or pregnancy when ACTH drive or steroid flux rises. (Pattern seen in case series.) PubMed Central

19. Coexisting endocrine states that increase ACTH (e.g., stress, illness) can exaggerate the phenotype by pushing adrenal androgen output higher even if the enzyme defect is modest. (Physiology consistent with HPA drive.) PubMed Central

20. Diagnostic confounders (not true causes) like licorice ingestion—these do not cause CRD, but they alter steroid enzymes and may confuse interpretation; clinicians must distinguish them from CRD. (Licorice mainly inhibits 11β-HSD2 → AME). PubMed Central+1

Symptoms and signs

1. Early or excessive body hair (hirsutism in females). Caused by high adrenal androgens responding to raised ACTH. Looks similar to PCOS. National Organization for Rare Disorders

2. Acne and oily skin. From androgen effects on hair follicles and sebaceous glands. PubMed Central

3. Irregular or infrequent periods (oligo-/amenorrhea). Androgen excess disrupts ovulation; cycles become irregular. National Organization for Rare Disorders

4. Infertility or subfertility in females. Chronic anovulation may interfere with conception. National Organization for Rare Disorders

5. Premature pubarche (early pubic/axillary hair) in children. A classic first clue in childhood CRD. PubMed

6. Advanced bone age with tall childhood growth that may level off later. ACTH-driven androgens speed skeletal maturation. PubMed

7. Adult-type body odor in a child. Another sign of early adrenal androgen action. PubMed Central

8. Clitoromegaly (rare) or labial/acne severity out of proportion for age. From sustained androgen exposure. National Organization for Rare Disorders

9. Male pattern baldness in severe female cases. Androgen-driven scalp hair loss can occur. National Organization for Rare Disorders

10. Insulin resistance features (e.g., acanthosis nigricans, central adiposity) in some patients, shared with other hyperandrogenic states like premature adrenarche/PCOS. PubMed Central

11. Mood or energy swings under stress (because tissue cortisol regeneration is impaired even if serum looks “normal”). (Mechanistic inference from 11β-HSD1 physiology.) Wiley Online Library

12. Normal blood pressure (in contrast to AME); hypertension is not a defining feature of CRD. (Differential point.) Wikipedia

13. No classic Cushing’s signs (no moon face, purple striae) because systemic cortisol is not chronically high; the problem is local cortisol regeneration. (Pathophysiology point.) PubMed Central

14. Headache or fatigue in some patients, especially when androgen excess is significant or with sleep disturbance; nonspecific but commonly reported in hyperandrogenic states. (Symptom pattern consistent with hyperandrogenism literature.) PubMed Central

15. Normal electrolytes (again distinguishing from licorice/AME where low potassium is common). Wikipedia

Diagnostic tests

A) Physical examination (bedside observations)

1. Growth and pubertal staging (Tanner staging).
   The clinician looks for early pubic/axillary hair, acne, body odor, and compares height/weight and maturation with age norms; early findings suggest adrenal androgen excess. PubMed Central

2. Ferriman–Gallwey hirsutism scoring.
   A visual scoring of terminal hair in 9 body areas; higher scores reflect androgen effect and help track treatment response over time. (Standard tool in hyperandrogenism.)

3. Skin inspection for acne and acanthosis nigricans.
   Acne signals androgen action; acanthosis suggests insulin resistance, sometimes traveling with premature adrenarche/PCOS-like states. PubMed Central

4. Blood pressure and edema check.
   Normal BP helps distinguish CRD from AME (which causes hypertension); edema is not typical in CRD. Wikipedia

5. Signs of virilization.
   Clitoromegaly, deepened voice, or male-pattern baldness indicate stronger or longer androgen exposure and prompt faster work-up. (General hyperandrogenism assessment.)

B) “Manual/office” tests (quick in-clinic measures)

6. Bone-age X-ray request and interpretation at the visit.
   A left-hand X-ray compared with standards shows if bones are maturing too fast (common in premature adrenarche/CRD). (Bridge to imaging section; commonly ordered at point of care.) PubMed

7. Waist circumference and BMI plotting.
   Helps assess metabolic risk that often coexists with adrenal androgen excess, informing counseling and follow-up. PubMed Central

8. Menstrual calendar review or ovulation tracking.
   Irregular cycles support hyperandrogenic anovulation; tracking helps monitor treatment impact. (Standard gynecologic assessment.)

9. Family pedigree mapping.
   Simple charting of relatives with early pubarche, hirsutism, or irregular menses can suggest hereditary CRD. (Genetic context.) PubMed Central

10. Medication/supplement screen (including licorice products).
    Important to exclude mimics (e.g., licorice → AME) and note 11β-HSD1 inhibitors that can blunt cortisone→cortisol. PubMed Central+1

C) Laboratory & pathological tests (core of diagnosis)

11. Morning serum androgens (DHEA-S, androstenedione, testosterone).
    Often elevated due to ACTH drive; the pattern looks like adrenal-predominant hyperandrogenism. PubMed Central

12. Basal ACTH and cortisol.
    Cortisol may be in the reference range (or mildly low-normal), which is why CRD is easy to miss; ACTH can be high-normal or elevated for the clinical picture. (Pathophysiologic expectation.) PubMed Central

13. 17-Hydroxyprogesterone (17-OHP).
    Can be elevated, but the profile does not match 21-hydroxylase CAH; helps rule in adrenal origin while excluding classic CAH types. (Differential Endo testing.) Oxford Academic

14. 24-hour urinary steroid profile by GC–MS.
    The key test: in CRD, the ratio of cortisol metabolites (THF + 5α-THF) to cortisone metabolite (THE) is reduced (often markedly), signaling impaired cortisone→cortisol regeneration. Reported cases show extremely low THF+allo-THF/THE ratios. Oxford Academic+1

15. Dynamic endocrine tests (low-dose dexamethasone suppression).
    Dexamethasone suppresses ACTH; androgen levels should fall if the source is ACTH-driven, supporting a functional CRD physiology. (Standard hyperandrogenism work-up logic.) Oxford Academic

16. ACTH stimulation test.
    Useful to examine adrenal reserve and patterns of steroidogenesis; helps distinguish CRD from enzyme blocks like 11β-hydroxylase deficiency or 21-hydroxylase deficiency. ScienceDirect

17. Genetic testing of H6PD and HSD11B1.
    Confirms the mechanism—H6PD mutations are common; HSD11B1 variants (e.g., R137C, K187N) define primary 11β-HSD1 deficiency. Oxford Academic+1

18. Sex hormone–binding globulin (SHBG) and free androgen index.
    Helps quantify biologically active androgen and contextualize severity of hyperandrogenism. (Standard PCOS/hyperandrogenism lab set.)

19. Metabolic panel (glucose, lipids) and insulin measures.
    Screens for insulin resistance or metabolic risk, which may coexist—guides lifestyle and follow-up plans. PubMed Central

20. Repeat urine steroid profiling during therapy.
    Tracks whether correcting ACTH drive (e.g., with physiologic glucocorticoid) normalizes the THF/THE balance, documenting response over time. (Follow-up principle derived from initial biomarker behavior.) Oxford Academic

D) “Electrodiagnostic / functional monitoring” (what’s realistically useful here)

While classic nerve-conduction/EMG tests have no role, two simple electronic monitors can help overall care:

• Ambulatory blood pressure or automated BP checks. Typically normal in CRD (helps distinguish from AME), but monitoring is prudent in hyperandrogenic states. Wikipedia

• Glucose monitoring (glucometer or CGM, if indicated). Screens for insulin resistance or impaired fasting glucose in those with metabolic risk features. PubMed Central

E) Imaging tests

• Bone-age X-ray. Often advanced in children with early adrenal androgen excess. PubMed

• Pelvic ultrasound in females. Looks for polycystic ovarian morphology (a phenocopy can occur) and excludes ovarian tumors if virilization is severe. (PCOS-adjacent evaluation.) National Organization for Rare Disorders

• Adrenal imaging (ultrasound/CT) only if red flags. Used to rule out androgen-secreting tumors when androgens are exceptionally high or unilateral findings are suspected. (General endocrine oncology practice.)

• Pituitary MRI if ACTH regulation looks abnormal or other pituitary signs exist; usually not needed in straightforward CRD. (Differential management principle.)

Non-pharmacological treatments

1. Condition education & shared decision-making
   Learning that CRD causes androgen excess due to ACTH drive (not “too much testosterone from the ovaries” alone) helps patients choose therapies that control ACTH and address symptoms (acne, hirsutism, menstrual issues). Education reduces anxiety, improves adherence, and aligns expectations for long-term monitoring. Oxford Academic+1

2. Healthy weight & metabolic care
   Although CRD is not obesity-driven, androgen excess can worsen metabolic health. Balanced diet, activity, and sleep hygiene support insulin sensitivity and cardiovascular risk, which parallels best practice in hyperandrogenic states like PCOS. PubMed Central

3. Skin & hair symptom care (dermatology)
   Non-drug acne routines (gentle cleansers, non-comedogenic moisturizers, UV protection) and cosmetic/laser hair removal can reduce distress while endocrine therapy is adjusted. Dermatologic measures relieve symptoms independent of hormone levels. PubMed Central

4. Menstrual tracking & fertility counseling
   Cycle tracking apps and pre-conception counseling help plan pregnancy timing; CRD-related hyperandrogenism may affect ovulation patterns, and coordinated endocrine-gynecology care supports fertility goals. GARD Information Center

5. Bone health habits
   If low-dose glucocorticoids are used chronically, emphasize calcium, vitamin D, resistance exercise, and fracture-risk assessment, reflecting general glucocorticoid safety guidance. Oxford Academic

6. Stress-dose literacy (if on chronic steroids)
   People taking suppressive glucocorticoids should know sick-day rules and carry a steroid card to prevent adrenal crisis during intercurrent illness or surgery—standard education borrowed from adrenal-insufficiency safety guidelines. ScienceDirect

7. Genetic counseling
   Families may benefit from counseling about autosomal inheritance patterns and testing of HSD11B1/H6PD when appropriate. Oxford Academic

8. Psychological support
   Visible symptoms (acne, hirsutism) and fertility worries affect mental health; brief counseling or support groups improve quality of life during treatment. PubMed Central

---

Drug treatments

Important: Doses below reflect published examples and general endocrine practice; clinicians individualize doses, timing, and formulations.

1. Dexamethasone (bedtime, ACTH suppression)
   Class: long-acting glucocorticoid. Why: suppresses nocturnal ACTH to reduce adrenal androgen production; it is not reliant on 11β-HSD1 for activation. Typical published dose: ~0.25–0.5 mg at night (e.g., 0.375 mg/d led to androgen suppression in a child with CRD). Mechanism: potent GR agonist with long half-life; directly lowers ACTH. Side-effects: Cushingoid features, weight gain, glucose intolerance, mood/sleep changes, bone loss—dose- and duration-dependent. PubMed+2Bioscientifica+2

2. Hydrocortisone (physiologic replacement—often insufficient alone in CRD)
   Class: short-acting glucocorticoid. Why: sometimes tried; however conversion/clearance issues in CRD limit effect on ACTH and androgens. Dosing: physiologic total daily 15–25 mg in divided doses in adrenal deficiency; in CRD, case experience shows inadequate androgen suppression with HC alone. Mechanism: GR agonist; short half-life. Side-effects: as other glucocorticoids. PubMed Central+1

3. Cortisone acetate (generally ineffective in CRD)
   Class: pro-drug of cortisol requiring 11β-HSD1 activation. Why/Outcome: Fails when 11β-HSD1 is impaired; classic reports show poor conversion with rise in cortisone instead of cortisol. Side-effects: insufficient control plus steroid risks if doses escalated. Oxford Academic+1

4. Prednisolone (intermediate-acting alternative)
   Class: intermediate-acting glucocorticoid. Why: sometimes used when dexamethasone adverse effects occur; once-daily morning dosing preferred to reduce HPA suppression, though for androgen control, evening/bedtime dosing may be considered case-by-case. Risks: glucocorticoid metabolic and bone effects. NCBI

5. Anti-androgens (e.g., spironolactone) for symptom control in females
   Class: androgen receptor antagonist/antimineralocorticoid. Why: reduces hirsutism/acne while endocrine control is optimized; used widely in hyperandrogenic states (apply contraception due to teratogenic risk of anti-androgens). Mechanism: blocks androgen receptor; increases SHBG modestly. Side-effects: hyperkalemia, menstrual irregularity, breast tenderness. (Evidence basis from hyperandrogenism literature.) PubMed Central

6. Combined oral contraceptives (COCs)
   Class: estrogen-progestin. Why: improve cycle regularity and lower free testosterone by raising SHBG and suppressing LH-driven ovarian androgen production; helpful for acne/hirsutism while ACTH is controlled. Risks: VTE risk in predisposed patients; blood-pressure and migraine considerations. PubMed Central

7. Metformin (metabolic support when insulin resistance co-exists)
   Class: insulin sensitizer. Why: addresses metabolic features seen with hyperandrogenism; improves cycles and acne in some PCOS-like contexts; adjunctive in CRD when indicated. Side-effects: GI upset, B12 deficiency with long-term use, rare lactic acidosis. PubMed Central

8. Topical dermatologic therapies (e.g., retinoids, benzoyl peroxide)
   Class: dermatologic agents. Why: direct acne control while endocrine therapy is titrated. Risks: dryness/irritation; photosensitivity with retinoids. PubMed Central

---

Dietary molecular supplements

There are no supplements proven to “fix” 11β-HSD1/H6PD mutations. The items below target symptom domains (skin, metabolism, bone) and must be clinician-approved, especially if on glucocorticoids.

1. Vitamin D – supports bone/muscle when on glucocorticoids; typical 800–2000 IU/d, individualized to serum 25(OH)D. Oxford Academic

2. Calcium (diet ± supplement) – 1000–1200 mg elemental/day from food/supplements to support bone. Oxford Academic

3. Omega-3 fatty acids – may modestly help inflammatory acne and cardiometabolic risk; typical 1–2 g/day EPA+DHA. (Adjunctive evidence base in dermatology/metabolic literature; clinician discretion.) PubMed Central

4. Inositol (myo-/D-chiro) – sometimes used in PCOS-like hyperandrogenism to support ovulation/metabolic profiles; discuss with clinician. PubMed Central

5. B12 (if on metformin) – consider 1000 mcg/week or per labs to prevent deficiency. PubMed Central

6. Topical niacinamide for acne – improves barrier/inflammation; part of dermatology care. PubMed Central

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved immune-booster, regenerative, or stem-cell medicines that correct the genetic enzyme problem in CRD. Experimental papers explore H6PD/11β-HSD1 pathway modulation in other diseases, but this is not a CRD therapy at present. Below are conceptual, not recommended agents to clarify the landscape:

1. Experimental H6PD blockade (oncology model) – Preclinical work shows pathway modulation can reshape glucocorticoid tone in tumors; not a therapy for CRD. Science

2. Gene therapy (conceptual) – In principle, correcting HSD11B1/H6PD could restore NADPH-dependent 11β-HSD1 activity; currently no human CRD trials. Oxford Academic

3. Anabolic bone agents (if steroid-related osteoporosis) – e.g., teriparatide per osteoporosis guidelines, not to treat CRD but to counter long-term steroid bone effects when indicated. Oxford Academic

(If you want, I can draft a strict “not-recommended/experimental” section with regulatory status for all six items.)

---

Procedures / surgeries

1. Cosmetic/dermatologic procedures – Laser hair removal, electrolysis, acne scar revision can relieve visible symptoms while endocrine control is optimized. Indication: persistent hirsutism/acne burden affecting quality of life. PubMed Central

2. Fertility procedures (if needed) – Intrauterine insemination/IVF are not CRD treatments but may assist conception when hyperandrogenism and ovulatory issues persist despite medical care. GARD Information Center

3. Surgical care for complications unrelated to enzyme defect – Rarely, procedures may address sequelae (e.g., dermatologic surgery for severe scarring). CRD itself does not require adrenal/ovarian surgery. PubMed Central

---

Prevention

• Early specialist diagnosis when hyperandrogenism presents in girls or premature pseudopuberty in boys prevents years of symptoms and suboptimal treatments. Karger

• Avoid self-escalation of glucocorticoids; inappropriate dosing risks Cushingoid complications. Oxford Academic

• Use lowest effective dexamethasone dose with regular review to minimize long-term risks. Oxford Academic

• Bone, glucose, BP monitoring during any chronic steroid use. Oxford Academic

• Sick-day rules card if on suppressive steroids. ScienceDirect

• Family genetic counseling for recurrence planning. Oxford Academic

• Differentiate from AME to avoid wrong therapy (e.g., mineralocorticoid-directed regimens). PubMed Central

---

When to see a doctor

See an endocrinologist promptly if you or your child has hirsutism, severe acne, irregular or absent periods, early puberty signs in boys, infertility concerns, or symptoms worsen despite acne/hair treatments. If you are on glucocorticoids and develop fever, vomiting, severe illness, surgery/injury, seek urgent care and follow stress-dose instructions. Karger+1

---

What to eat and what to avoid

• Do: balanced whole-food diet, adequate protein and fiber, regular meals to support glucose control. Oxford Academic

• Do: calcium + vitamin D through food and supplements if on long-term steroids. Oxford Academic

• Do: hydration and heart-healthy fats (e.g., fish) for metabolic support. Oxford Academic

• Do: steady sleep schedule—helps endocrine rhythm. Oxford Academic

• Avoid: high-sugar ultra-processed foods that worsen insulin resistance. Oxford Academic

• Avoid: unnecessary licorice products if AME is suspected in the differential (licorice can inhibit 11β-HSD2 and mimic AME). PubMed Central

• Avoid: excess alcohol; it impairs sleep and metabolic control. Oxford Academic

• Avoid: unsupervised supplements promising “hormone balance.” Oxford Academic

• Discuss caffeine if it worsens acne/sleep; personalize rather than blanket restrict. PubMed Central

• Focus: consistent, sustainable habits over fad diets. Oxford Academic

---

FAQs

1. Is CRD the same as PCOS?
   No. CRD mimics PCOS signs (acne, hirsutism, irregular periods) because of ACTH-driven adrenal androgens. Urine steroids and genetics separate them. Endocrine Abstracts

2. Is CRD dangerous?
   It’s rarely life-threatening itself, but symptoms can be very distressing. If glucocorticoids are used, monitoring prevents treatment complications. Oxford Academic

3. What test confirms CRD?
   Urinary steroid profile (GC–MS) showing low cortisol:cortisone metabolite ratio, plus HSD11B1/H6PD genetic testing. Oxford Academic

4. Why doesn’t cortisone acetate help?
   It must be converted by 11β-HSD1—the very step that’s weak in CRD. Oxford Academic

5. Why does dexamethasone help?
   It directly suppresses ACTH and doesn’t depend on 11β-HSD1 activation. Bioscientifica

6. What dose of dexamethasone is used?
   Low doses (e.g., ~0.25–0.5 mg at night) have been reported; clinicians individualize to minimize side effects. PubMed

7. Can boys be affected?
   Yes—may show premature pseudopuberty; pediatric endocrine care is needed. Karger

8. Is hypertension part of CRD?
   No. Hypertension points to AME (11β-HSD2 deficiency) rather than CRD. PubMed Central

9. Will anti-androgens cure CRD?
   They reduce symptoms but don’t correct the enzyme problem. Core management targets ACTH drive. PubMed Central

10. Can I get pregnant with CRD?
    With coordinated endocrine and gynecology care, many do. Some need adjunct fertility support. GARD Information Center

11. Is gene therapy available?
    Not currently for CRD. Research into the pathway exists but no approved gene/stem-cell treatments. Science

12. Do I need a low-salt diet?
    Not specifically for CRD; that advice is for AME. Follow general heart-healthy nutrition. PubMed Central

13. Should I avoid licorice?
    Licorice worsens AME, not CRD—but avoid excessive licorice if AME is in the differential. PubMed Central

14. How often are follow-ups?
    Typically every 3–6 months initially to titrate therapy and monitor glucose, blood pressure, growth (children), and bone health if on steroids. Oxford Academic

15. Where can I find specialists?
    Look for endocrinology and medical genetics teams familiar with rare adrenal disorders. GARD Information Center

 

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 21, 2025.